Thursday 26th November 2020: 14:00 BST
Scientists routinely use cell lines as healthy and diseased tissue models within drug development. They are easy to maintain, a stable platform and relatively inexpensive. However, they often do not reflect what is physiologically relevant in vivo. This is where primary cells may be a more advantageous choice for complex physiological disease and now an integral platform within Immuno-Oncology Research.
Kristina Kremer (Miltenyi Biotec B.V. & Co. KG)
‘Density-gradient-free solutions for cell isolation’
Sofie Pattijn (ImmunXperts)
‘The use of primary cells for Immuno Oncology Drug Development’
Facilitator: David Blakey (MiNA Therapeutics)